Viral Infection Severity Reduction via 3Dpol Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate in effectively reducing the severity of viral infections, such as picornavirus and herpesvirus infections, and in enhancing innate immunity in mammals.
Innovation Solution
Administration of nucleic acids or proteins encoding the picornavirus 3Dpol polypeptide, specifically using viral vectors like lentiviral vectors, to increase the expression of innate immunity-related genes, thereby enhancing the mammal's immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to treat viral infections, then treatment is provided, but the severity of viral infections is not effectively reduced and innate immunity is not sufficiently enhanced
Solution Approach 1:
The patent applies preliminary action by administering nucleic acids or proteins encoding picornavirus 3Dpol polypeptide before or during viral infection to proactively enhance innate immunity. This pre-positioning of immune-enhancing agents allows the mammal's immune system to be primed and responsive before the full force of viral infection takes hold, rather than merely reacting to established infection
Solution Approach 2:
The patent uses nucleic acids or proteins encoding picornavirus 3Dpol polypeptide as intermediary substances that mediate between the external environment and the mammal's innate immune system. These intermediaries deliver the functional information or catalytic activity needed to upregulate innate immunity genes, bridging the gap between current treatment methods and the desired immune enhancement outcome
2Reliability
If viral vectors like lentiviral vectors are used to deliver nucleic acids, then expression of innate immunity genes is increased, but device complexity increases
Solution Approach 1:
The patent applies universality by using viral vectors like lentiviral vectors that can deliver nucleic acids encoding picornavirus 3Dpol polypeptide to multiple cell types and tissues throughout the mammal's body. This single vector system performs the multi-function of transducing diverse target cells, achieving widespread upregulation of innate immunity genes across different organ systems without requiring separate delivery mechanisms for each tissue type
Solution Approach 2:
The patent employs copying by using viral vectors that replicate their genetic material within host cells. The lentiviral vector copies its RNA genome into DNA, which then integrates into the host cell's genome and directs continuous production of the picornavirus 3Dpol polypeptide. This self-copying mechanism ensures sustained expression of immune-enhancing proteins without requiring repeated administrations of the complex vector system
Data Source
AI summary
This document relates to methods and materials involved in treating and/or preventing and/or reducing the severity of a viral infection present in a mammal. For example, methods and materials for reducing the severity of a viral infection present in a mammal (e.g., a human) are provided.